The Team

 
Dr Andreas Schatzlein, Dr med vet
Chief Executive Officer
 
Andreas has a track record of medicines development and translational research in industry and academia. A veterinary surgeon by training, he obtained a PhD/DVM in nanomedicines and was part of the team that started IDEA GmbH to commercialise the technology.
He then re-joined academia and became leader of the Cancer Research UK’s Experimental Therapeutics and Gene Medicines Group and Director of the GCLP Analytical Services Unit at the Beatson Laboratories, Glasgow. His research has attracted more then £7.5m in funding and has been featured repeatedly in the media (TV, radio, print).
 
Professor Ijeoma Uchegbu, BPharm, PhD
Chief Scientific Officer
Professor Uchegbu obtained her PhD from the School of Pharmacy, University of London, before moving to a lectureship in the Department of Pharmaceutical Sciences, University of Strathclyde, eventually being appointed to a Chair in Drug Delivery at the same university.  At the University of Strathclyde Uchegbu worked on the self-assembly of polymers, creating new polymers capable of forming high stability nanosystems and functional nanomedicines.  An appointment to a chair in Pharmaceutical Nanoscience at the School of Pharmacy, University of London followed, just prior to the launch of Nanomerics. Uchegbu has received a number of awards, notably the UK’s Women of Outstanding Achievement Award (2007) in Science Engineering and Technology (http://www.ukrc4setwomen.org/) awarded by the former Department and Trade and Industry’s (now Department of Business, Innovation and Skills) United Kingdom Resource Centre.
 
Professor Lisbeth Illum, MPharm, PhD, DSc
Non-exec Director
Professor Illum is a successful nanotechnology pioneer and entrepreneur as a highly regarded drug delivery scientist with an illustrious academic career.  She was co-founder and MD of DanBiosyst Ltd from 1989 until its $US34m acquisition by West Pharmaceuticals in 1998.
She was Managing Director of Phaeton Research, a company specializing in advanced drug delivery and more recently served as CEO of Critical Pharmaceuticals, a drug delivery company specialised in the delivery of biopharmaceuticals and macromolecules. She was awarded her M. Pharm, Ph.D and D.Sc. from the Royal Danish School of Pharmacy and is a Special Professor at The University of Nottingham. She has published more than 315 scientific papers to be among the top 100 most cited scientists on pharmacology and has co-edited four books including “Peptide Drug Delivery Systems”.